FTX-449: Prevention of AML Relapse
Dual inhibitor: Inhibition of this gene could kill cancer stem cell and FLT3-ITD* mutation
Focusing on the development of peptide receptor radionuclide therapy (PRRT).
Develop innovative drugs to treat insulin-dependent diabetes
In order to restore normal insulin production, and normalize glucose metabolism
Developing Neosubstrate Expression Modulators library and synthetic lethal screening to achieve targeted protein degradation by binding to Cereblon for certain therapeutic areas.
F5 Therapeutics Incorporated
Discovering and developing a new class of peptide-based therapeutics enabled by a proprietary platform technology, headquartered in Chicago, IL.
Grove Biopharma, Inc.
Targeting lncRNA using oligonucleotide-based drugs to treat heart fibrosis
Haya Therapeutics SA
I-MAB was founded in 2016 and registered in the Cayman Islands. It focuses on the R & D and production of biological antibody drugs in the field of tumor immunity and autoimmune disease treatment.
Developing the targeted enzymatic hydrolysis (TED) technology based innovative drugs
Aim to right some undruggable targets to improve drug delivery efficiency, overcome drug resistance, reduce toxicity and expand the adaptation disease range